Echocardiographic Evaluation of Initial Ambrisentan Plus Phosphodiesterase Type 5 Inhibitor on Right Ventricular Pulmonary Artery Coupling in Severe Pulmonary Arterial Hypertension Patients

Echocardiographic Evaluation of Initial Ambrisentan Plus Phosphodiesterase Type 5 Inhibitor on Right Ventricular Pulmonary Artery Coupling in Severe Pulmonary Arterial Hypertension Patients

Introductionambrisentan and phosphodiesterase type 5 inhibitor (PDE5i) have been approved for treating patients with pulmonary arterial hypertension (PAH). Echocardiographic right ventricular pulmonary artery coupling (RVPAC) has been shown to be a valid non-invasive and alternative measurement meth...

Full description

Bibliographic Details
Main Authors: Wei-Fang Lan, Yan Deng, Bin Wei, Kai Huang, Ping Dai, Shan-Shan Xie, Dan-dan Wu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-05-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
pulmonary arterial hypertension
right ventricular pulmonary arterial coupling
echocardiography
combination therapy
right ventricular remodeling
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2022.843606/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2022.843606/full

Similar Items